Curaxis Pharmaceutical Corporation is a specialty pharmaceutical company dedicated to finding cures for major age-related diseases. Curaxis' initial focus is Alzheimer's Disease (or AD). The lead product is a patented treatment that has shown the potential for treating and halting the progression of this devastating disease.

Today, over 5,300,000 Americans suffer with Alzheimer's Disease. It is estimated that more than $100 billion is spent annually in the United States to treat and care for those with this ailment. Sadly, these numbers are growing every day as the situation for many patients and their families grows desperate, despite the millions of dollars spent annually to find the answer to effectively treating this disease.

Curaxis Pharmaceutical is moving to guide our patented treatment through the necessary clinical trials in order to make it available for patients as quickly as possible. Management believes this product represents a major new development in the battle against Alzheimer's Disease. Currently, no medications or treatments halt or materially slow the progression of this disease. Our research results provide a very strong scientific explanation for the age-related onset of the disease, as well as its progressive nature.

Curaxis’ strategy is to initiate enrollment and dose the first patient in a Phase 2 clinical trial in women with mild to moderate Alzheimer’s disease in 2010. This major step for the Company will signify the next stage in the development of Curaxis Pharmaceutical and a major milestone towards commercialization of Curaxis' treatment for Alzheimer’s Disease.